ClinicalTrials.gg
RecruitingNCT07739875Updated Jul 31, 2026

Ecological Momentary Intervention for Post-Stroke Anomia

An interventional study of Semantic Feature Ecological Momentary Intervention in Post-Stroke Chronic Aphasia, sponsored by Northeastern University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Northeastern University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

Anomia (i.e., impaired word retrieval) is one of the most common and debilitating deficits experienced by stroke survivors with aphasia, an acquired disorder characterized by impaired language. Although many anomia treatments exist, treatment response is modest and inconsistent across studies, and the extent of generalization to everyday contexts-the therapy gold standard-is largely unknown. The critical gap between actual outcomes and the therapeutic potential of naming therapy is tied to problems with current treatment delivery practices (i.e., low/unknown dosage, massed practice delivery, and decontextualized training). In this research, we aim to demonstrate that a novel smartwatch-based ecological momentary intervention (EMI) that delivers high-dosage semantic feature training throughout daily life has the potential for overcoming these issues. Every day for six weeks, 20 PWA will complete 24 trials of semantic feature EMI distributed over the day (from 10am-8pm) and delivered by a smartwatch. The EMI trial flow will include five steps: 1) a prompt alert and audiovisual "Ready to name a picture?" cue, 2) a first naming attempt after a YES response, 3) the repetition of an auditory model, 4) semantic feature verification via yes/no questions, and 5) a second naming attempt. To contextualize training further, trained items will be clustered into location categories (e.g., home, pharmacy), and we will use the mobile device's location detection to match PWA's location and item category for \~50% of trials. In Aim #1, we will establish preliminary efficacy of this EMI by determining the extent to which semantic feature EMI improves naming of trained items and generalizes to untrained, related contexts. We predict that the EMI will significantly improve 1) naming of trained items and semantically related, untrained items relative to semantically unrelated items and 2) subjective and objective measures of functional communication effectiveness. Given the novelty of our EMI, the second two aims will focus on identifying key factors of semantic feature EMI user experience (Aim #2) and trends between therapy response and the treatment delivery factors of dosage, trial spacing, and item-location congruence (Aim #3). The proposed research is innovative because of the novel use of EMI for aphasia, our combined application of distributed practice and context-dependent training, and the future promise of extending our system to other types of evidence-based treatment and to other clinical populations, as well as to in-situ "just-in-time" interventions that can intervene in real time during the moment of communication breakdown. The significance of this research lies in its ability to provide technology that automatically tracks dosage metrics; its potential for increasing knowledge regarding which therapy delivery factors impact outcomes; and its promise for providing PWA alternative paths to receive therapy. Successful completion of this research will lead to an R01 application aimed at establishing the efficacy of this novel therapy compared to gold-standard, clinician-provided treatment and determining which active treatment ingredients contribute to outcomes.

Read the detailed description

Anomia (i.e., impaired word retrieval) is one of the most common and debilitating deficits experienced by stroke survivors with aphasia, an acquired language disorder. Although many anomia treatments exist, treatment response is modest and inconsistent across studies, and the extent of generalization to everyday contexts-the ultimate goal of therapy-is largely unknown.

The critical gap between actual patient outcomes and the therapeutic potential of naming therapy is tied to treatment delivery limitations. Clinician-provided therapy requires hours of face time between a provider and patient, which limits the total dosage of therapy that can be delivered. Substantial evidence from cognitive psychology and emerging support from aphasia indicates distributed practice is best for long-term retention of treatment gains, yet standard aphasia therapy does not follow this model. Skill transference benefits from context, but most aphasia treatment remains decontextualized, with people with aphasia (PWA) completing sessions in clinic rooms outside of the real-world settings in which they live and communicate. In the current U.S. healthcare system, high-dosage, distributed and contextualized anomia treatment is infeasible.

In ecological momentary intervention (EMI), therapy is provided repeatedly throughout the day over time via prompts from a mobile device. Thus, EMI has inherent capacity for providing high-dosage, distributed, and contextualized therapy, but it is unused in stroke thus far. Research in PWA in EMI's sister method, ecological momentary assessment, does exist, including work by our team. In our work, 14 PWA and 14 controls completed a three-week smartwatch audio-based protocol in which they overtly named prompted pictures while going about daily life. We established feasibility of this method, including finding similar protocol compliance between PWA (77% response rate), controls (78%), and the extant EMA literature (79%). The objective of this phase 1 trial is to test a novel EMI based on our smartwatch naming protocol and semantic feature analysis therapy but with therapy trials temporally distributed throughout everyday life. We selected semantic feature analysis because it is one of the most effective and widely used anomia therapies, and it can be incorporated into our EMI system.

Twenty PWA will complete six weeks of EMI in their community. The EMI trial flow will include five steps: 1) a prompt alert and "Ready to name a picture?" cue, 2) a first naming attempt after a YES response, 3) the repetition of an auditory model, 4) semantic feature verification questions, and 5) a second naming attempt. To test the effects of contextualized training, trained items will be clustered into location categories (e.g., home, pharmacy), and we will use the smartwatch's location detection to match PWA's location and item category for \~50% of trials. All PWA will be scheduled to receive the same number of prompts (i.e., treatment trials) but typical variability in EMI compliance will induce natural variation between PWA in other treatment delivery factors (i.e., total dosage and trial spacing). With this paradigm, we will pursue the following aims:

Aim #1: Determine the extent to which semantic feature EMI improves naming of trained items and generalizes to untrained, related contexts. EMI efficacy will be determined by measuring a) change in trained item accuracy and b) generalization to untrained, semantically related items and functional communication. Consistent with spreading activation theory, we expect EMI to improve naming of trained items and untrained, semantically related items and result in modest (but significant) gains in functional communication.

Aim #2: Identify key factors of semantic feature EMI user experience. To learn from PWA how to optimize user experience and our protocol, we will use brief, weekly surveys and an exit interview to explore user perceptions of EMI system usability, acceptability, utility, and burden, as well as impressions of the research protocol. Qualitative content analysis will be used to identify exit interview themes. Our pilot work suggests facilitators of positive EMI user experience will be pre-EMI device training, aphasia-friendly EMI flow, and options to opt out of prompts when needed; we will explore these topics and others related to our novel EMI.

Aim #3: Identify trends between therapy response and treatment delivery factors. Treatment delivery factors will include item-location congruence, dosage (total minutes), and trial spacing (minutes between trials). Inter-subject variability in EMI response rate will allow us to disentangle these variables and interrogate their preliminary impact on treatment response in this phase 1 trial. We will explore them more fully in a future R01.

Achieving these aims will lay the foundation for an R01 aimed at establishing the efficacy of this novel EMI compared to standard clinician-provided semantic feature analysis and determining which active treatment ingredients contribute to outcomes. Our team is uniquely positioned to carry out this research, bringing a strong complement of interdisciplinary expertise in speech pathology and mobile health technologies with a record of successful collaboration. Our proposed EMI solution can address important limits to treatment effectiveness for PWA and holds translation potential to other treatments and communication disorders.

02

Conditions studied

  • Post-Stroke Chronic Aphasia

Browse trials for

Keywords

  • Anomia
  • Semantic Feature Analysis
  • Ecological Momentary Intervention
03

In context

Anomia

47 studies on the registry are indexed under Anomia; 9 are open to participants now.

This study's planned enrollment of 24 is close to the median of 24 across 43 interventional studies indexed under Anomia.

Browse Anomia studies →

Lead sponsor

Northeastern University is the lead sponsor of 55 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Current/pre-stroke English proficiency
  2. Normal/corrected-to-normal vision and hearing
  3. Medical stability
  4. History of left hemisphere stroke at least six months prior to enrollment.

Upon enrollment, additional testing will be required to determine eligibility for receiving the therapy, including 1) presence of aphasia as determined by scores on language tests and the study team's clinical judgment (spearheaded by PI Meier) and 2) at least 48 items eligible for training based on the baseline naming probe, a necessity to ensure PWA who do not require training on the targeted word list are not unnecessarily included in the treatment group.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of neurological disease affecting the brain (besides stroke)
  2. Major psychiatric disorders
  3. Recent history of falls within six months of enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Semantic Feature Ecological Momentary Intervention

    Participants will wear a smartwatch every day for 6 weeks. Between 10am and 8pm, prompts will be delivered from the watch that correspond to a semantic feature training trial. This intervention is similar to semantic feature verification treatment but delivered via the watch through the day rather than by a clinician in a single session.

    Behavioral: Semantic Feature Ecological Momentary Intervention

Interventions

  • BehavioralSemantic Feature Ecological Momentary Intervention

    If answered, each prompt will correspond to a single picture naming training trial. The trial flow will include five steps: (1) an initial vibration/chime prompt and audiovisual "Ready to name a picture?" question, (2) a first naming attempt upon a button YES response to the "Ready?" question, (3) an audiovisual model of the target word, (4) an audiovisual cue of "Get ready to answer some questions!" followed by a series of six yes/no semantic feature questions, and (5) a second and final naming attempt upon a YES response to the audiovisual "Ready to name a picture?" question. If the participant taps NO to any "Ready?" question or ignores the prompt, the trial flow will end, and they will be re-prompted once more 10 minutes later. If they ignore or respond NO to the re-prompt, that trial will be skipped. PWA will have 10 seconds to respond to Steps #2, #3, and #5.

06

What researchers measure

Primary outcomes

  1. Accuracy on Trained Items

    Each participant will receive semantic feature intervention for 24 trained words. Accuracy will be assessed via naming probes administered before, during (at the end of each week), and after therapy. Accuracy will be coded as 0 for incorrect and 1 for correct on each naming probe. Improvement in accuracy on trained items will be compared to change over time on a set of 24 untrained words that are not semantically related to the trained items.

    Time frame: 7 weeks (from before the intervention to the one-week follow-up)

Secondary outcomes

  1. Accuracy on Semantically Related, Untrained Items

    A list of 12 items that are related in meaning (i.e., semantically related) to the 24 trained items will be identified and monitored over the course of therapy. Specifically, accuracy for these items will also be assessed via naming probes administered before, during (at the end of each week), and after therapy. Accuracy will be coded as 0 for incorrect and 1 for correct on each naming probe. Improvement in accuracy on the 12 semantically related, untrained items will be compared to change over time on a set of 12 untrained words that are not semantically related to the trained items.

    Time frame: 7 weeks (from before the intervention to the one-week follow-up)

  2. Change in Functional Communication

    The Aphasia Communication Outcome Measure (Hula et al., 2015) is a standardized assessment of subjective ratings of functional communication in which people with aphasia indicate how effectively they can accomplish what they want without help or taking too long on a variety of everyday communication tasks (e.g., ask for information from store employees, talk about current/previous work) via a visual scale. The AphasiaBank Discourse Protocol (MacWhinney et al., 2011) is a series of tasks in which individuals respond to open-ended questions, describe single pictures and picture sequences, describe a procedure, and retell a story in order to obtain measures reflecting discourse-level skills. Change in functional communication from before to after therapy will be determined by assessing the change in the Aphasia Communication Outcome Measure standardized score and change in percent correct information units produced in a set of the AphasiaBank tasks.

    Time frame: 7 weeks (from before the intervention to the one-week follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 32 non-industry interventional studies with no phase under Anomia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 62. This study's planned 14 months is below that.

Counting every sponsor, half of 32 studies reached it within 41 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
May 19, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07739875
Lead sponsor
Northeastern University
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
May 19, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 31, 2026

Study contacts

Erin L Meier, PhD
Contact
e.meier@northeastern.edu
617-373-7438
The Aphasia Network Lab
Contact
tanlab.northeastern@gmail.com
857-342-9694
Erin L Meier, PhD
principal investigator · Northeastern University
Stephen S. Intille, PhD
principal investigator · Northeastern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion